A part of Watch Media

MedWatchSunday2 April 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Per Wold-Olsen officially stepped down as GN's chair at the company's AGM | Foto: Mik Eskestad

Former GN chair says there have been no acquisition signs from Demant owner

Per Wold-Olsen left the chairperson position two weeks ago after 15 years – he now reveals there haven’t been acquisition talks behind closed doors during his time at the company.
  • JPMorgan says GN prognosis is too "conservative"
  • William Demant Invest report reveals GN Group stake

For subscribers

Foto: Caitlin Ochs

JPMorgan says GN prognosis is too "conservative"

For subscribers

Foto: Ws Audiology / Pr

Owners inject EUR 100m into WS Audiology

Foto: Gn/pr

GN board member steps down due to family health issues

For subscribers

Michael Løvbjerg, CEO and co-founder of Lizn | Foto: Lizn / Pr

New hearing company 14 years in the making – "We expect to rise to the top"

For subscribers

Foto: Gn/pr

William Demant Invest report reveals GN Group stake

For subscribers

  • Foto: Gn/pr

    DNB surprised by GN's lack of backup plan

    The lack of support for GN’s scrapped capital raise was to be anticipated, says a DNB analyst, meaning it would have made sense to make a plan B in advance.

    For subscribers

  • Foto: Gn/pr

    GN's scrapped capital raise: Norges Bank voted no, William Demant Invest abstained

    While the Norwegian bank contributed substantially to GN’s decision to retract a proposed DKK 7bn capital raise, William Demant Invest did not stand in the way.

    For subscribers

  • Foto: Gn/pr

    Activist fund denies rumors – does not own GN stock

    One media said Elliot Investment Management was secretly exploring a potential GN organizational split, but the fund now says it has never owned shares in the hearing company.

    For subscribers

  • Foto: Gn/pr

    William Demant Invest has nothing to say on scrapped GN capital raise

    Despite being a major shareholder of the hearing company, the investment firm maintains it ”won’t comment on any potential future suggestions” GN makes to pay off its debts.

    For subscribers

  • Jukka Pekka Pertola was elected GN group's new chairman of the board on Wednesday | Foto: Jukka Pekka Pertola / Privat

    New GN chair wants to find debt solution – but can't say when

    GN has to find alternative solutions to solve a debt problem that shareholders will accept – and the work begins now, says newly elected Chairman Jukka Pekka Pertola. 

    For subscribers

  • Foto: Gn/pr

    Shareholders' association to GN: ”Reach out to Willian Demant Invest"

    The suggestion to enter dialog with the investment company, which some think is the best bid for buying GN, was met by cheers at the annual general meeting.

    For subscribers

  • Per Wold-Olsen speaking at GN Group's AGM in Ballerup, Denmark | Foto: Christopher Due Karlsson

    Departing GN chair: An organizational split would be unwise

    Per Wold-Olsen, who is stepping down as chairman of GN Group today, says that competitors have started copying the company’s unique business model.

    For subscribers

  • Foto: Gn/pr

    GN retracts proposal to raise capital

    In February, the hearing firm said it wanted to raise DKK 7bn on the stock exchange, but now says shareholder support was unlikely to be gained.

    For subscribers

  • Foto: Euha/foto Rechnitz

    GN, Sivantos VA market shares decrease in February – Demant and Starkey gain

    The US public hearing aid sales channel saw an overall drop in February volumes compared to January. 

    For subscribers

  • Foto: Pr/dnb

    DNB: GN has million-dollar wiggle room in rights issue

    Although the Norwegian financial services group thinks less than the announced full DKK 7bn amount would suffice, it does not believe GN leadership will change its plans to raise.

    For subscribers

  • Foto: Gn/pr

    Analyst sees no signs of acquisition bids for GN Group

    Now would be the time to come with a bid for the company – GN convenes its annual meeting with shareholders next week, where they will be asked to approve a rights issue.

    For subscribers

  • Tom Austadm CEO of Oculaudio | Foto: Privat/LinkedIn

    Cochlear partners with Norwegian startup on "hearing aid" glasses

    Cochlear sees hearing loss with new eyes as it partners with a Norwegian startup developing a pair of hearing eyeglasses.

    For subscribers

  • Foto: Demant / Pr

    Analysts raise expectations for Demant following annual report

    Despite the new targets for the Danish hearing aid manufacturer, analysts’ projections are still in the low end of Demant’s own outlook for 2023.

    For subscribers

  • Foto: Amplifon / Pr

    Amplifon reports "solid revenue growth" in first months of the year

    However, the world’s biggest hearing aid retailer still disappointed analysts slightly in Q4’22.

    For subscribers

  • Steen Thygesen, CEO of Audientes | Foto: Audientes / Pr

    Audientes explains missing Q4 sales citing unexpected Indian market

    During the now-concluded financial year, Audientes learned that hearing loss in India is ”more profound” than expected, and software platform upgrade to the company’s product was needed.

    For subscribers

  • Foto: Gn/pr

    Jefferies raises GN share price target

    The investment bank also raises its stock recommendation to ”buy” for the hearing firm.

    For subscribers

  • Foto: Pr/gn

    GN’s rights issue could be less than announced

    In the beginning of February, GN Group said it intended to raise DKK 7bn (USD 1bn) through a share issuance, but Deputy Chair Jukka Pekka Pertola now reports that the sum is subject to change.

    For subscribers

  • Foto: Euha/foto Rechnitz

    GN, WSA recede at Veterans Affairs in January – Demant and Sonova win out

    GN continues to slide at the US public hearing aid sales channel while Sonova reverses its December result.

    For subscribers

  • Kathmandu, capital of Nepal | Foto: Thomas Borberg

    Audientes expands distribution network in Nepal

    A collaboration deal with Nepal-based M.B. Meditech will bring Audientes’s self-fitting hearing aid, Ven, to Nepalese customers.

    For subscribers

  • Steen Thygesen, CEO of Audientes | Foto: Audientes / Pr

    Embattled Audientes broaches subject of company divestment

    Audientes CEO Steen Thygesen opens up about the different paths forward for the company, imposing a third-quarter deadline for clearing up the hearing firm’s future.

    For subscribers

Latest news

  • Top news from MedWatch this week – 31 Mar
  • CHMP recommends nine drugs in March – 31 Mar
  • Coloplast challenges its biggest catheter competitor in clinical contest – 31 Mar
  • Former Bavarian Nordic chairman sees opportunities in Johnson & Johnson's RSV exit – 31 Mar
  • Former GN chair says there have been no acquisition signs from Demant owner – 31 Mar
  • Novo Nordisk helps Canada resolve Ozempic issue – 31 Mar
  • New study says AstraZeneca drug rarely leads to RSV mutations – 31 Mar
  • Danish health minister to answer questions about Novo Nordisk sponsorship of patient group – 30 Mar
  • Bluebird Bio expects delay on FDA sickle cell drug application – 30 Mar
  • WHO mulls over labeling obesity drugs as essential medicines – 30 Mar
See all

Jobs

  • Regulatory Affairs Specialist

  • Nordic Medical Advisor

  • Director Regulatory Affairs

  • Experienced Patent Counsel

  • Good Clinical Practice (GCP) inspectors for the Danish Medicines Agency

  • System Engineer Medical Device

  • Manager QC - Microbiology or Biochemistry

  • Senior consultant dentist for the maxillofacial surgery department at Rigshospitalet

  • Key Partnership Development Manager

  • International & Partnership Manager

  • Technologist / Senior Technologist

  • Senior Data Manager

  • Director/Senior Director, Commercial Excellence

  • Corporate QA Specialist, Missionpharma

  • Nordic Brand Manager

  • Senior Automation Engineer & Technical Lead, I2R

  • Senior IM Process Specialist Medico, CARMO

  • Research Scientist, 2-year position

  • Manager QC Raw Materials

  • Director, Oncology and Translational Science

  • In-house QA Consultant

  • Lead Data Architect

  • Senior Clinical Trial Manager

  • Procurement Manager, Indirect Materials

  • Head of Regulatory Affairs

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge